ArticleThe Journal of antimicrobial chemotherapy2026
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Piperacillin Population Pharmacokinetics in Plasma and Peritoneal Fluid and Dosing Optimization in Children Undergoing Liver Transplant: An Optimome Study.Clinical pharmacology and therapeutics · 2026Observational
- Achieving therapeutic antibiotic levels during intermittent dosing of meropenem and piperacillin-tazobactam in critically ill children: the ATACC study.Antimicrobial agents and chemotherapy · 2026Observational
- Initial Dosage Optimization of Tacrolimus in Connective Tissue Disease-Associated Interstitial Lung Disease Patients: An Exploratory Study.Drug design, development and therapy · 2026Article
- Building a Beta-Lactam Model-Informed Precision Dosing Service in a Quaternary Care Children's Hospital.Clinical and translational science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesWe sought to develop population pharmacokinetic (PopPK) models of total and free piperacillin in critically ill children and young adults. We investigated the impact of kidney function and injury biomarkers and the effect of time on pharmacokinetic (PK) parameters.
methodsWe enrolled patients admitted to a paediatric ICU and prescribed piperacillin/tazobactam. We collected residual blood from clinical samples for total and free piperacillin concentrations. PopPK models were developed using nonlinear mixed effects modelling. Specific covariates of interest included time after antibiotic initiation, using a 48 h threshold, and urine neutrophil gelatinase-associated lipocalin (uNGAL), a tubular injury biomarker. Monte Carlo simulations investigated target attainment using different dosing regimens.
resultsTotal (n = 695) and free concentrations (n = 639) from 139 patients were best described by two-compartment models. Creatinine-based estimated glomerular filtration rate (eGFR), uNGAL, and time >48 h after initial dosing were significant covariates of both total and free piperacillin clearance. Regarding central volume, albumin and cumulative fluid balance were significant covariates on total and free piperacillin, respectively. Simulations showed a common regimen of 100 mg/kg piperacillin/tazobactam every 6 h over a 30 min infusion is only sufficient for targeting bacteria with MICs of 2 mg/L or less in patients >30 kg with eGFR <150 mL/min/1.73 m2 or <30 kg with eGFR <90 mL/min/1.73 m2.
conclusionUsing a large sample of critically ill children, we developed total and free piperacillin population PK models and newly identified uNGAL and time as significant covariates on piperacillin clearance. These models may be used for model-informed precision dosing after external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.